This article is more than 5 years old. Information may no longer be current.
Sarah Cannon Research Institute announces two promotions
Click Here to Manage Email Alerts
Sarah Cannon Research Institute announced two promotions.
Erika P. Hamilton, MD, has been named director of the breast and gynecologic cancer research program.
Erika P. Hamilton
She has been involved with the program for 3 years. Her research focuses on novel therapies, personalized medicine and immunotherapy.
“Erika has quickly become a recognized thought leader in the field of women’s cancer research by not only her research peers, but also the pharmaceutical and biotech industry for her contributions to drug development,” Howard A. “Skip” Burris, MD, Sarah Cannon’s chief medical officer and president of clinical operations, said in a press release. “Focused on ensuring patients have the best care from diagnosis through survivorship, Erika is dedicated to bringing forward new treatment options and diagnostics that are helping to transform how we identify and treat a variety of breast and gynecological cancers.”
David Spigel , MD, has been promoted to chief scientific officer.
David Spigel
He will oversee the development and operations of Sarah Cannon's clinical research program. He also will work with research physician leaders, and biotech and pharmaceutical companies to ensure the latest innovative treatments are available to patients.
Spigel joined Sarah Cannon in 2003 as the director of the lung cancer research program. He has played a significant role in the development of immunotherapies and other targeted medicines in clinical trials at Sarah Cannon.
“For more than 10 years, [Spigel] has been instrumental in bringing the latest targeted therapies to patients through our lung cancer research program,” Burris said in the release. “With his insight and expertise, we have been able to make great strides in advancing the standard of care for patients across tumor types. Under his leadership, we look forward to continuing to enhance our clinical trial offerings and drug development program to further our mission of advancing therapies for patients.”